Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
The analysis of short-term operating activity ratios indicates a general decline in operational efficiency over the observed period from April 2022 through March 2026. There is a consistent trend toward longer processing and collection cycles, which has extended the overall operating and cash conversion cycles.
- Inventory Management
- A steady deterioration in inventory efficiency is evident. The inventory turnover ratio decreased from 2.77 in April 2022 to 2.13 by March 2026. Consequently, the average inventory processing period expanded from 132 days to 172 days, suggesting a slower movement of goods and a potential increase in stockpiling or a decline in sales velocity.
- Receivables Management
- Receivables turnover exhibits a gradual downward trend, moving from 6.08 to 5.44 over the period. This decline is mirrored in the average receivable collection period, which rose from 60 days to 67 days. While less volatile than inventory metrics, this indicates a slight weakening in the efficiency of credit collections.
- Payables Management
- Payables turnover remained relatively volatile, starting at 3.26 and ending at 2.96. The average payables payment period fluctuated between 111 and 145 days, ending at 123 days in March 2026. These fluctuations suggest a dynamic approach to managing supplier obligations, with periodic extensions of payment terms to preserve liquidity.
- Operating and Cash Conversion Cycles
- The operating cycle, which combines the inventory processing and receivable collection periods, lengthened significantly from 192 days to 239 days. The cash conversion cycle followed a similar upward trajectory, increasing from 80 days in April 2022 to 116 days in March 2026, despite a temporary dip to 93 days in December 2025. This indicates that more capital is being tied up in the operating process for longer durations.
- Working Capital Utilization
- The working capital turnover ratio demonstrates extreme volatility, characterized by irregular spikes, most notably reaching 284.99 in June 2025 before settling at 66.14 in March 2026. Such drastic fluctuations typically suggest significant shifts in the net working capital base, potentially resulting from strategic corporate restructuring or substantial changes in the balance of current assets and liabilities.
AI Ask an analyst for more
Turnover Ratios
Average No. Days
Inventory Turnover
| Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Cost of products sold | 8,106) | 7,968) | 7,303) | 7,628) | 7,357) | 7,128) | 6,963) | 6,869) | 6,511) | 6,798) | 6,606) | 6,462) | 6,687) | 7,765) | 7,807) | 7,919) | 7,598) | ||||||
| Inventories | 14,583) | 14,191) | 14,146) | 13,412) | 12,659) | 12,444) | 12,603) | 12,169) | 11,383) | 11,181) | 11,198) | 12,888) | 12,809) | 12,483) | 11,675) | 11,437) | 10,990) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Inventory turnover1 | 2.13 | 2.13 | 2.08 | 2.17 | 2.24 | 2.21 | 2.15 | 2.20 | 2.32 | 2.37 | 2.46 | 2.23 | 2.36 | 2.49 | 2.68 | 2.69 | 2.77 | ||||||
| Benchmarks | |||||||||||||||||||||||
| Inventory Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | — | 3.68 | 3.65 | 3.42 | 3.71 | 4.04 | 4.09 | 4.86 | 4.83 | 4.98 | 4.74 | 4.30 | 4.53 | 4.87 | 5.54 | 4.99 | 4.96 | ||||||
| Amgen Inc. | — | 1.93 | 1.92 | 1.88 | 1.88 | 1.84 | 1.75 | 1.42 | 1.14 | 0.89 | 1.41 | 1.38 | 1.31 | 1.30 | 1.34 | 1.40 | 1.48 | ||||||
| Bristol-Myers Squibb Co. | 5.20 | 5.18 | 5.31 | 5.18 | 5.28 | 5.46 | 3.57 | 3.72 | 3.70 | 4.02 | 4.33 | 4.39 | 3.93 | 4.33 | 4.77 | 4.59 | 4.55 | ||||||
| Danaher Corp. | 3.90 | 4.04 | 3.67 | 3.60 | 3.79 | 4.15 | 3.60 | 3.59 | 3.73 | 3.80 | 3.53 | 3.58 | 3.50 | 4.03 | 3.80 | 3.71 | 3.87 | ||||||
| Eli Lilly & Co. | 0.85 | 0.80 | 0.83 | 0.84 | 0.96 | 1.11 | 1.05 | 1.16 | 1.17 | 1.23 | 1.40 | 1.37 | 1.36 | 1.54 | 1.86 | 1.79 | 1.93 | ||||||
| Gilead Sciences Inc. | — | 3.51 | 3.47 | 3.40 | 3.55 | 3.66 | 3.62 | 3.33 | 3.59 | 3.64 | 3.49 | 3.45 | 3.57 | 3.75 | 4.71 | 4.50 | 4.50 | ||||||
| Merck & Co. Inc. | — | 2.46 | 2.27 | 2.25 | 2.43 | 2.49 | 2.45 | 2.39 | 2.42 | 2.54 | 2.63 | 2.66 | 2.72 | 2.95 | 3.10 | 3.06 | 2.74 | ||||||
| Pfizer Inc. | — | 1.51 | 1.46 | 1.52 | 1.60 | 1.65 | 1.66 | 2.05 | 2.15 | 2.45 | 2.65 | 2.31 | 3.07 | 3.82 | 3.62 | 3.66 | 3.67 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.74 | 0.66 | 0.64 | 0.64 | 0.63 | 0.64 | 0.64 | 0.65 | 0.66 | 0.70 | 0.72 | 0.69 | 0.67 | 0.65 | 0.83 | 0.96 | 1.27 | ||||||
| Thermo Fisher Scientific Inc. | — | 4.85 | 4.47 | 4.57 | 4.82 | 5.06 | 4.62 | 4.83 | 4.93 | 5.06 | 4.83 | 4.64 | 4.62 | 4.60 | 4.29 | 4.03 | 3.87 | ||||||
| Vertex Pharmaceuticals Inc. | — | 0.98 | 0.99 | 1.06 | 1.14 | 1.27 | 1.37 | 1.53 | 1.65 | 1.71 | 1.71 | 1.90 | 2.06 | 2.35 | 2.69 | 2.70 | 2.83 | ||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Inventory turnover
= (Cost of products soldQ1 2026
+ Cost of products soldQ4 2025
+ Cost of products soldQ3 2025
+ Cost of products soldQ2 2025)
÷ Inventories
= (8,106 + 7,968 + 7,303 + 7,628)
÷ 14,583 = 2.13
2 Click competitor name to see calculations.
An analysis of operating activity reveals a persistent decline in inventory efficiency over the analyzed period. While the cost of products sold has experienced fluctuations and a subsequent recovery, inventory levels have grown at a faster rate, resulting in a diminished turnover ratio.
- Inventory Turnover Ratio
- A consistent downward trajectory is observed, with the ratio decreasing from 2.77 in April 2022 to 2.13 by March 2026. The most pronounced decline occurred between April 2022 and July 2023, after which the ratio largely fluctuated within a lower range of 2.08 to 2.46. This trend indicates a lengthening of the duration required to convert inventory into sales.
- Inventory Valuation
- Inventories exhibited a general upward trend, increasing from 10,990 million USD in April 2022 to 14,583 million USD by March 2026. Despite a temporary contraction during the second half of 2023, where levels dropped to a low of 11,181 million USD in December 2023, a steady and significant accumulation of stock occurred from early 2024 through the end of the period.
- Cost of Products Sold (COPS)
- The cost of products sold showed notable volatility, peaking at 7,919 million USD in July 2022 before declining to a low of 6,462 million USD in July 2023. From 2024 onward, a steady growth phase is evident, with the value reaching 8,106 million USD by March 2026. However, the increase in COPS was insufficient to offset the growth in inventory levels, contributing to the overall reduction in turnover efficiency.
AI Ask an analyst for more
Receivables Turnover
| Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Sales to customers | 24,062) | 24,564) | 23,993) | 23,743) | 21,893) | 22,520) | 22,471) | 22,447) | 21,383) | 21,395) | 21,351) | 21,519) | 20,894) | 23,706) | 23,791) | 24,020) | 23,426) | ||||||
| Accounts receivable, trade, less allowances | 17,721) | 17,178) | 17,611) | 17,846) | 16,020) | 14,842) | 16,174) | 15,794) | 14,946) | 14,873) | 14,798) | 16,777) | 16,350) | 16,160) | 15,890) | 16,139) | 15,594) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Receivables turnover1 | 5.44 | 5.48 | 5.23 | 5.08 | 5.58 | 5.98 | 5.42 | 5.48 | 5.73 | 5.73 | 5.91 | 5.36 | 5.65 | 5.88 | 6.04 | 5.92 | 6.08 | ||||||
| Benchmarks | |||||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | — | 4.86 | 4.67 | 4.62 | 4.60 | 5.16 | 4.84 | 4.69 | 4.55 | 4.87 | 4.83 | 4.88 | 4.95 | 5.16 | 5.38 | 5.10 | 5.29 | ||||||
| Amgen Inc. | — | 3.67 | 4.06 | 3.85 | 4.03 | 4.72 | 4.26 | 4.26 | 4.16 | 3.70 | 4.17 | 4.34 | 4.34 | 4.46 | 4.60 | 4.62 | 4.81 | ||||||
| Danaher Corp. | 6.49 | 6.28 | 6.46 | 6.74 | 6.79 | 6.75 | 6.77 | 7.15 | 7.02 | 6.09 | 6.15 | 6.64 | 6.89 | 6.40 | 7.09 | 6.81 | 6.87 | ||||||
| Eli Lilly & Co. | 3.92 | 3.67 | 3.69 | 3.76 | 4.07 | 4.09 | 3.97 | 3.53 | 4.56 | 3.75 | 3.93 | 3.93 | 3.68 | 4.14 | 4.35 | 4.57 | 4.64 | ||||||
| Gilead Sciences Inc. | — | 5.89 | 5.60 | 6.01 | 6.51 | 6.47 | 6.14 | 5.92 | 5.84 | 5.78 | 5.68 | 6.43 | 6.43 | 5.65 | 6.16 | 6.60 | 7.18 | ||||||
| Merck & Co. Inc. | — | 5.52 | 5.30 | 5.37 | 5.92 | 6.24 | 5.55 | 5.37 | 5.40 | 5.81 | 5.71 | 5.29 | 5.56 | 6.27 | 6.22 | 5.93 | 5.49 | ||||||
| Pfizer Inc. | — | 5.27 | 4.40 | 5.29 | 5.27 | 5.55 | 4.18 | 4.93 | 5.09 | 5.33 | 6.25 | 7.66 | 7.57 | 9.16 | 6.21 | 6.68 | 6.99 | ||||||
| Regeneron Pharmaceuticals Inc. | 2.60 | 2.50 | 2.51 | 2.53 | 2.53 | 2.29 | 2.27 | 2.36 | 2.51 | 2.31 | 2.35 | 2.47 | 2.42 | 2.28 | 2.47 | 2.76 | 3.41 | ||||||
| Thermo Fisher Scientific Inc. | — | 5.01 | 4.91 | 5.03 | 5.07 | 5.23 | 5.13 | 5.33 | 5.36 | 5.21 | 5.19 | 5.43 | 5.53 | 5.53 | 5.76 | 5.53 | 5.21 | ||||||
| Vertex Pharmaceuticals Inc. | — | 5.85 | 6.02 | 6.03 | 6.15 | 6.85 | 6.07 | 6.24 | 5.68 | 6.31 | 6.27 | 6.11 | 5.95 | 6.19 | 6.28 | 6.26 | 6.15 | ||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Receivables turnover
= (Sales to customersQ1 2026
+ Sales to customersQ4 2025
+ Sales to customersQ3 2025
+ Sales to customersQ2 2025)
÷ Accounts receivable, trade, less allowances
= (24,062 + 24,564 + 23,993 + 23,743)
÷ 17,721 = 5.44
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a general downward trend in receivables turnover efficiency over the period from April 2022 to March 2026. While the company maintained a relatively stable collection cycle in the early stages of the period, there is an observable shift toward lower turnover ratios, indicating a slower conversion of credit sales into cash.
- Receivables Turnover Trajectory
- The receivables turnover ratio peaked at 6.08 in April 2022 and experienced a gradual decline, reaching a period low of 5.08 by June 2025. Although intermittent recoveries occurred, such as the increase to 5.98 in December 2024, the overall trend indicates a reduction in the frequency with which accounts receivable are cleared during the annual cycle.
- Revenue and Receivable Correlation
- Sales to customers exhibited volatility, with a notable dip throughout 2023 before recovering to a peak of 24,564 million US$ in September 2025. However, the accounts receivable balance grew more aggressively in the later stages, rising from approximately 15,594 million US$ in April 2022 to 17,721 million US$ by March 2026. This growth in the receivables balance has outpaced the growth in sales, directly contributing to the compression of the turnover ratio.
- Operational Efficiency Observations
- A significant contraction in efficiency is observed in the first half of 2025, where the turnover ratio dropped to 5.08. This coincides with a sharp increase in trade receivables to 17,846 million US$. The subsequent stabilization around 5.44 by March 2026 suggests that while the extreme dip was corrected, the company has not returned to the higher efficiency levels observed in 2022.
AI Ask an analyst for more
Payables Turnover
| Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Cost of products sold | 8,106) | 7,968) | 7,303) | 7,628) | 7,357) | 7,128) | 6,963) | 6,869) | 6,511) | 6,798) | 6,606) | 6,462) | 6,687) | 7,765) | 7,807) | 7,919) | 7,598) | ||||||
| Accounts payable | 10,460) | 11,991) | 9,625) | 9,464) | 9,545) | 10,311) | 8,954) | 8,848) | 8,174) | 9,632) | 8,355) | 10,443) | 9,909) | 11,703) | 10,153) | 9,765) | 9,309) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Payables turnover1 | 2.96 | 2.52 | 3.06 | 3.07 | 2.97 | 2.66 | 3.03 | 3.03 | 3.23 | 2.76 | 3.29 | 2.75 | 3.05 | 2.66 | 3.08 | 3.15 | 3.26 | ||||||
| Benchmarks | |||||||||||||||||||||||
| Payables Turnover, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | — | 5.09 | 4.29 | 4.12 | 5.25 | 6.74 | 5.99 | 5.01 | 6.10 | 5.32 | 5.22 | 5.67 | 4.97 | 4.08 | 5.30 | 5.09 | 4.65 | ||||||
| Bristol-Myers Squibb Co. | 3.38 | 3.90 | 3.42 | 2.61 | 3.52 | 3.88 | 3.43 | 3.05 | 3.12 | 3.28 | 3.75 | 3.38 | 3.20 | 3.33 | 3.82 | 3.41 | 3.25 | ||||||
| Danaher Corp. | 5.68 | 5.45 | 5.78 | 5.62 | 5.57 | 5.52 | 6.04 | 5.84 | 5.88 | 5.58 | 5.63 | 5.82 | 5.68 | 5.45 | 5.61 | 5.00 | 5.04 | ||||||
| Eli Lilly & Co. | 2.47 | 2.05 | 2.37 | 2.27 | 2.61 | 2.61 | 2.70 | 2.56 | 2.88 | 2.73 | 2.81 | 2.65 | 3.07 | 3.43 | 4.24 | 4.21 | 5.24 | ||||||
| Gilead Sciences Inc. | — | 8.72 | 7.66 | 10.65 | 8.47 | 7.50 | 7.49 | 12.57 | 10.69 | 11.81 | 9.90 | 9.06 | 8.99 | 6.25 | 11.22 | 11.89 | 11.43 | ||||||
| Merck & Co. Inc. | — | 3.72 | 3.53 | 3.82 | 3.98 | 3.72 | 4.26 | 4.39 | 4.48 | 4.11 | 4.59 | 4.58 | 4.34 | 4.08 | 5.16 | 4.86 | 4.25 | ||||||
| Pfizer Inc. | — | 3.07 | 3.32 | 3.44 | 3.30 | 3.17 | 3.67 | 4.60 | 4.19 | 3.72 | 5.07 | 3.92 | 4.78 | 5.04 | 5.49 | 6.17 | 6.66 | ||||||
| Regeneron Pharmaceuticals Inc. | 2.24 | 2.24 | 2.30 | 2.83 | 2.84 | 2.50 | 3.87 | 3.32 | 2.67 | 2.99 | 3.43 | 3.14 | 2.69 | 2.65 | 3.74 | 4.00 | 5.39 | ||||||
| Thermo Fisher Scientific Inc. | — | 7.27 | 8.23 | 8.53 | 8.25 | 8.18 | 9.63 | 9.85 | 9.91 | 8.97 | 10.41 | 10.82 | 9.35 | 7.67 | 9.93 | 8.84 | 7.96 | ||||||
| Vertex Pharmaceuticals Inc. | — | 3.58 | 3.83 | 3.59 | 3.49 | 3.71 | 3.73 | 4.27 | 3.81 | 3.46 | 3.13 | 3.16 | 3.41 | 3.55 | 8.23 | 5.01 | 5.52 | ||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Payables turnover
= (Cost of products soldQ1 2026
+ Cost of products soldQ4 2025
+ Cost of products soldQ3 2025
+ Cost of products soldQ2 2025)
÷ Accounts payable
= (8,106 + 7,968 + 7,303 + 7,628)
÷ 10,460 = 2.96
2 Click competitor name to see calculations.
The payables turnover ratio exhibits a fluctuating pattern over the analyzed period, generally ranging between 2.52 and 3.29. A cyclical trend is evident, characterized by recurring declines in turnover efficiency during the final quarters of the calendar year, suggesting a seasonal shift in the management of supplier obligations.
- Payables Turnover Volatility
- The ratio reached its peak of 3.29 in October 2023, indicating a period of accelerated payment to suppliers. Conversely, the lowest point was recorded in December 2025 at 2.52. This variance suggests periodic adjustments in payment terms or changes in procurement timing.
- Year-End Cyclicality
- A consistent downward trend in the turnover ratio is observed every December (2.66 in 2022, 2.76 in 2023, 2.66 in 2024, and 2.52 in 2025). These troughs coincide with significant peaks in accounts payable balances, most notably the 11.99 billion USD recorded in December 2025, indicating a systematic increase in short-term liabilities at the close of the fiscal year.
- Operational Cost and Liability Correlation
- The cost of products sold experienced a contraction through 2023, reaching a low of 6.46 billion USD in July 2023, before entering a steady growth phase from March 2024 (6.51 billion USD) through March 2026 (8.11 billion USD). While operational costs increased, accounts payable did not follow a linear growth path, resulting in the observed fluctuations in the turnover ratio as the company balanced procurement growth with payment schedules.
AI Ask an analyst for more
Working Capital Turnover
| Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Current assets | 59,173) | 55,624) | 54,611) | 54,498) | 71,551) | 55,893) | 53,249) | 57,817) | 57,002) | 53,495) | 53,703) | 60,567) | 64,388) | 55,294) | 65,236) | 63,847) | 60,424) | ||||||
| Less: Current liabilities | 57,716) | 54,126) | 50,869) | 54,180) | 56,903) | 50,321) | 51,759) | 53,933) | 48,725) | 46,282) | 44,370) | 54,170) | 60,373) | 55,802) | 45,543) | 44,821) | 43,390) | ||||||
| Working capital | 1,457) | 1,498) | 3,742) | 318) | 14,648) | 5,572) | 1,490) | 3,884) | 8,277) | 7,213) | 9,333) | 6,397) | 4,015) | (508) | 19,693) | 19,026) | 17,034) | ||||||
| Sales to customers | 24,062) | 24,564) | 23,993) | 23,743) | 21,893) | 22,520) | 22,471) | 22,447) | 21,383) | 21,395) | 21,351) | 21,519) | 20,894) | 23,706) | 23,791) | 24,020) | 23,426) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Working capital turnover1 | 66.14 | 62.88 | 24.63 | 284.99 | 6.10 | 15.94 | 58.86 | 22.29 | 10.35 | 11.81 | 9.37 | 14.06 | 23.02 | — | 4.88 | 5.02 | 5.57 | ||||||
| Benchmarks | |||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Amgen Inc. | — | 9.85 | 5.66 | 5.35 | 8.36 | 5.40 | 4.83 | 5.19 | 3.39 | 2.25 | 0.81 | 0.84 | 0.82 | 3.82 | 2.52 | 3.67 | 4.34 | ||||||
| Bristol-Myers Squibb Co. | 5.84 | 7.83 | 6.20 | 8.09 | 6.87 | 7.79 | 8.49 | 12.50 | 15.56 | 4.60 | 10.47 | 5.53 | 5.55 | 8.30 | 5.75 | 4.92 | 6.24 | ||||||
| Danaher Corp. | 3.83 | 4.13 | 7.39 | 5.71 | 8.27 | 8.85 | 8.73 | 8.10 | 3.60 | 4.22 | 2.18 | 3.08 | 3.81 | 4.20 | 5.00 | 5.43 | 5.91 | ||||||
| Eli Lilly & Co. | 3.97 | 3.19 | 2.71 | 4.92 | 4.38 | 10.32 | 6.06 | 12.62 | 5.45 | — | 31.79 | 12.21 | 5.77 | 31.84 | 14.71 | 19.45 | 8.19 | ||||||
| Gilead Sciences Inc. | — | 4.43 | 5.12 | 8.14 | 6.27 | 3.99 | 9.22 | 17.98 | 26.58 | 5.61 | 6.74 | 84.15 | 9.14 | 8.42 | 8.56 | 6.87 | 6.68 | ||||||
| Merck & Co. Inc. | — | 4.28 | 3.39 | 5.77 | 6.19 | 6.19 | 5.86 | 5.14 | 9.68 | 9.29 | 6.69 | 8.86 | 5.63 | 5.16 | 5.58 | 6.39 | 6.09 | ||||||
| Pfizer Inc. | — | 10.58 | 6.08 | 10.68 | 6.64 | 8.64 | 5,036.00 | — | 29.17 | — | 1.62 | 2.03 | 6.89 | 11.00 | 3.83 | 5.05 | 6.10 | ||||||
| Regeneron Pharmaceuticals Inc. | 1.14 | 1.05 | 1.05 | 1.08 | 1.01 | 0.97 | 0.88 | 0.87 | 0.86 | 0.82 | 0.87 | 0.92 | 0.90 | 0.96 | 1.09 | 1.14 | 1.46 | ||||||
| Thermo Fisher Scientific Inc. | — | 3.30 | 5.90 | 3.64 | 4.20 | 4.87 | 4.61 | 3.96 | 4.38 | 4.05 | 4.86 | 7.40 | 10.13 | 5.46 | 5.40 | 6.03 | 6.13 | ||||||
| Vertex Pharmaceuticals Inc. | — | 1.64 | 1.92 | 1.82 | 1.78 | 1.83 | 1.82 | 1.92 | 1.07 | 0.93 | 0.87 | 0.90 | 0.93 | 0.85 | 0.90 | 0.93 | 0.97 | ||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Working capital turnover
= (Sales to customersQ1 2026
+ Sales to customersQ4 2025
+ Sales to customersQ3 2025
+ Sales to customersQ2 2025)
÷ Working capital
= (24,062 + 24,564 + 23,993 + 23,743)
÷ 1,457 = 66.14
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals significant volatility in working capital management relative to a stable revenue stream. While sales to customers remained consistent throughout the period, the working capital turnover ratio exhibited extreme fluctuations, driven primarily by sharp contractions in working capital.
- Revenue Stability
- Sales to customers maintained a consistent range, fluctuating between a low of 20,894 million USD in April 2023 and a high of 24,564 million USD in December 2025. This stability indicates a steady demand for products and a predictable top-line performance over the analyzed timeframe.
- Working Capital Volatility
- Working capital demonstrated erratic behavior, characterized by several sharp declines. A notable deficit of 508 million USD occurred in December 2022, followed by a recovery and subsequent instability. A significant trough was observed in June 2025, where working capital dropped to 318 million USD, representing a substantial decrease from the 14,648 million USD recorded in March 2025.
- Working Capital Turnover Analysis
- The turnover ratio transitioned from a stable range of 4.88 to 5.57 in 2022 to a highly volatile state in subsequent years. Because the ratio is sensitive to the denominator, the sharp reductions in working capital led to exponential spikes in turnover, most notably reaching 284.99 in June 2025 and exceeding 60.00 in late 2025 and early 2026. These peaks suggest periods where the organization operated with minimal net current assets relative to its sales volume.
- Operational Efficiency Trends
- The shift from a turnover ratio of approximately 5.0 in early 2022 to consistently higher figures—often exceeding 20.0 after 2023—indicates a fundamental change in the working capital structure. The trend suggests a strategic or situational move toward leaner operating liquidity, although the extreme variance in the ratio suggests inconsistency in the maintenance of short-term asset levels.
AI Ask an analyst for more
Average Inventory Processing Period
| Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Inventory turnover | 2.13 | 2.13 | 2.08 | 2.17 | 2.24 | 2.21 | 2.15 | 2.20 | 2.32 | 2.37 | 2.46 | 2.23 | 2.36 | 2.49 | 2.68 | 2.69 | 2.77 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||
| Average inventory processing period1 | 172 | 171 | 176 | 168 | 163 | 165 | 169 | 166 | 158 | 154 | 149 | 164 | 155 | 147 | 136 | 136 | 132 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | — | 99 | 100 | 107 | 98 | 90 | 89 | 75 | 75 | 73 | 77 | 85 | 81 | 75 | 66 | 73 | 74 | ||||||
| Amgen Inc. | — | 189 | 190 | 194 | 195 | 199 | 209 | 257 | 321 | 411 | 259 | 265 | 279 | 281 | 272 | 260 | 247 | ||||||
| Bristol-Myers Squibb Co. | 70 | 70 | 69 | 70 | 69 | 67 | 102 | 98 | 99 | 91 | 84 | 83 | 93 | 84 | 76 | 79 | 80 | ||||||
| Danaher Corp. | 94 | 90 | 99 | 101 | 96 | 88 | 101 | 102 | 98 | 96 | 104 | 102 | 104 | 91 | 96 | 98 | 94 | ||||||
| Eli Lilly & Co. | 428 | 454 | 441 | 435 | 379 | 329 | 349 | 316 | 312 | 298 | 261 | 267 | 268 | 237 | 196 | 204 | 189 | ||||||
| Gilead Sciences Inc. | — | 104 | 105 | 108 | 103 | 100 | 101 | 110 | 102 | 100 | 105 | 106 | 102 | 97 | 78 | 81 | 81 | ||||||
| Merck & Co. Inc. | — | 148 | 160 | 162 | 150 | 147 | 149 | 153 | 151 | 144 | 139 | 137 | 134 | 124 | 118 | 119 | 133 | ||||||
| Pfizer Inc. | — | 242 | 251 | 239 | 229 | 222 | 219 | 178 | 170 | 149 | 138 | 158 | 119 | 95 | 101 | 100 | 99 | ||||||
| Regeneron Pharmaceuticals Inc. | 491 | 556 | 571 | 570 | 582 | 572 | 573 | 562 | 553 | 519 | 508 | 532 | 549 | 562 | 440 | 379 | 287 | ||||||
| Thermo Fisher Scientific Inc. | — | 75 | 82 | 80 | 76 | 72 | 79 | 76 | 74 | 72 | 76 | 79 | 79 | 79 | 85 | 91 | 94 | ||||||
| Vertex Pharmaceuticals Inc. | — | 373 | 369 | 345 | 320 | 287 | 267 | 238 | 222 | 214 | 213 | 192 | 177 | 156 | 136 | 135 | 129 | ||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 2.13 = 172
2 Click competitor name to see calculations.
The analysis of operating activity indicates a consistent decline in inventory management efficiency between April 2022 and March 2026. There is a clear inverse correlation between the turnover rates and the duration of the inventory processing cycle, suggesting a slowdown in the movement of goods.
- Inventory Turnover Performance
- A sustained downward trajectory is observed in the inventory turnover ratio, which decreased from a high of 2.77 in April 2022 to 2.13 by March 2026. This trend indicates a diminishing capacity to cycle through inventory stocks. Although a temporary increase to 2.46 was noted in October 2023, the overall movement reflects a progressive reduction in turnover velocity.
- Average Inventory Processing Period
- The average inventory processing period demonstrates a corresponding upward trend, expanding from 132 days in April 2022 to 172 days by March 2026. The processing duration reached its peak of 176 days in September 2025. This extension signifies that inventory is remaining in the system for significantly longer durations before being sold.
- Operational Implications
- The increase in the processing period by 40 days over the analyzed timeframe suggests a potential accumulation of unsold stock or a shift in supply chain dynamics. The convergence of the turnover ratio at 2.13 during the final two quarters indicates that the decline in efficiency has reached a plateau, establishing a new, slower baseline for operating activity.
AI Ask an analyst for more
Average Receivable Collection Period
| Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Receivables turnover | 5.44 | 5.48 | 5.23 | 5.08 | 5.58 | 5.98 | 5.42 | 5.48 | 5.73 | 5.73 | 5.91 | 5.36 | 5.65 | 5.88 | 6.04 | 5.92 | 6.08 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||
| Average receivable collection period1 | 67 | 67 | 70 | 72 | 65 | 61 | 67 | 67 | 64 | 64 | 62 | 68 | 65 | 62 | 60 | 62 | 60 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | — | 75 | 78 | 79 | 79 | 71 | 75 | 78 | 80 | 75 | 76 | 75 | 74 | 71 | 68 | 72 | 69 | ||||||
| Amgen Inc. | — | 99 | 90 | 95 | 91 | 77 | 86 | 86 | 88 | 99 | 88 | 84 | 84 | 82 | 79 | 79 | 76 | ||||||
| Danaher Corp. | 56 | 58 | 56 | 54 | 54 | 54 | 54 | 51 | 52 | 60 | 59 | 55 | 53 | 57 | 51 | 54 | 53 | ||||||
| Eli Lilly & Co. | 93 | 99 | 99 | 97 | 90 | 89 | 92 | 103 | 80 | 97 | 93 | 93 | 99 | 88 | 84 | 80 | 79 | ||||||
| Gilead Sciences Inc. | — | 62 | 65 | 61 | 56 | 56 | 59 | 62 | 62 | 63 | 64 | 57 | 57 | 65 | 59 | 55 | 51 | ||||||
| Merck & Co. Inc. | — | 66 | 69 | 68 | 62 | 58 | 66 | 68 | 68 | 63 | 64 | 69 | 66 | 58 | 59 | 62 | 66 | ||||||
| Pfizer Inc. | — | 69 | 83 | 69 | 69 | 66 | 87 | 74 | 72 | 69 | 58 | 48 | 48 | 40 | 59 | 55 | 52 | ||||||
| Regeneron Pharmaceuticals Inc. | 140 | 146 | 146 | 144 | 144 | 160 | 161 | 155 | 146 | 158 | 156 | 148 | 151 | 160 | 148 | 132 | 107 | ||||||
| Thermo Fisher Scientific Inc. | — | 73 | 74 | 73 | 72 | 70 | 71 | 68 | 68 | 70 | 70 | 67 | 66 | 66 | 63 | 66 | 70 | ||||||
| Vertex Pharmaceuticals Inc. | — | 62 | 61 | 61 | 59 | 53 | 60 | 58 | 64 | 58 | 58 | 60 | 61 | 59 | 58 | 58 | 59 | ||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 5.44 = 67
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a general decline in the efficiency of receivables management from April 2022 through March 2026. This trend is characterized by a gradual decrease in the receivables turnover ratio and a corresponding extension of the average collection period.
- Receivables Turnover Trends
- The turnover ratio exhibits a downward trajectory, starting at 6.08 in April 2022 and reaching a period low of 5.08 in June 2025. Although temporary recoveries occurred, such as a peak of 5.98 in December 2024, the overall trend indicates a reduction in the frequency with which the company converts its receivables into cash.
- Average Receivable Collection Period
- The collection period reflects a widening gap in cash realization, moving from an initial 60 days in early 2022 to a peak of 72 days in June 2025. The data shows a period of relative stability during 2022, followed by a steady increase throughout 2023 and 2024, suggesting a slowing of the cash conversion cycle.
- Period Stabilization and Final Observations
- Following the peak in mid-2025, the collection period appears to have stabilized, remaining constant at 67 days through March 2026. This represents a net increase in the collection cycle of approximately 11.7% compared to the initial 60-day baseline established at the start of the observed period.
AI Ask an analyst for more
Operating Cycle
| Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Average inventory processing period | 172 | 171 | 176 | 168 | 163 | 165 | 169 | 166 | 158 | 154 | 149 | 164 | 155 | 147 | 136 | 136 | 132 | ||||||
| Average receivable collection period | 67 | 67 | 70 | 72 | 65 | 61 | 67 | 67 | 64 | 64 | 62 | 68 | 65 | 62 | 60 | 62 | 60 | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Operating cycle1 | 239 | 238 | 246 | 240 | 228 | 226 | 236 | 233 | 222 | 218 | 211 | 232 | 220 | 209 | 196 | 198 | 192 | ||||||
| Benchmarks | |||||||||||||||||||||||
| Operating Cycle, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | — | 174 | 178 | 186 | 177 | 161 | 164 | 153 | 155 | 148 | 153 | 160 | 155 | 146 | 134 | 145 | 143 | ||||||
| Amgen Inc. | — | 288 | 280 | 289 | 286 | 276 | 295 | 343 | 409 | 510 | 347 | 349 | 363 | 363 | 351 | 339 | 323 | ||||||
| Danaher Corp. | 150 | 148 | 155 | 155 | 150 | 142 | 155 | 153 | 150 | 156 | 163 | 157 | 157 | 148 | 147 | 152 | 147 | ||||||
| Eli Lilly & Co. | 521 | 553 | 540 | 532 | 469 | 418 | 441 | 419 | 392 | 395 | 354 | 360 | 367 | 325 | 280 | 284 | 268 | ||||||
| Gilead Sciences Inc. | — | 166 | 170 | 169 | 159 | 156 | 160 | 172 | 164 | 163 | 169 | 163 | 159 | 162 | 137 | 136 | 132 | ||||||
| Merck & Co. Inc. | — | 214 | 229 | 230 | 212 | 205 | 215 | 221 | 219 | 207 | 203 | 206 | 200 | 182 | 177 | 181 | 199 | ||||||
| Pfizer Inc. | — | 311 | 334 | 308 | 298 | 288 | 306 | 252 | 242 | 218 | 196 | 206 | 167 | 135 | 160 | 155 | 151 | ||||||
| Regeneron Pharmaceuticals Inc. | 631 | 702 | 717 | 714 | 726 | 732 | 734 | 717 | 699 | 677 | 664 | 680 | 700 | 722 | 588 | 511 | 394 | ||||||
| Thermo Fisher Scientific Inc. | — | 148 | 156 | 153 | 148 | 142 | 150 | 144 | 142 | 142 | 146 | 146 | 145 | 145 | 148 | 157 | 164 | ||||||
| Vertex Pharmaceuticals Inc. | — | 435 | 430 | 406 | 379 | 340 | 327 | 296 | 286 | 272 | 271 | 252 | 238 | 215 | 194 | 193 | 188 | ||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 172 + 67 = 239
2 Click competitor name to see calculations.
The overall operating cycle exhibits a sustained upward trajectory over the analyzed period, expanding from 192 days in April 2022 to 239 days by March 2026. This expansion indicates a longer duration between the initial outlay for inventory and the final collection of cash from sales, signaling a reduction in short-term operational efficiency.
- Average Inventory Processing Period
- A significant and consistent increase is observed in the inventory processing period, which rose from 132 days in April 2022 to 172 days in March 2026. The peak occurred in September 2025 at 176 days. This trend suggests a slowing of inventory turnover, which may be attributed to increased stock holdings or a deceleration in product movement.
- Average Receivable Collection Period
- The receivable collection period demonstrated more stability than inventory, although a slight upward trend is evident. Starting at 60 days in April 2022, the period fluctuated and reached a maximum of 72 days in June 2025 before settling at 67 days by March 2026. This indicates that while cash collection from customers remains relatively controlled, there has been a marginal increase in the time required to convert receivables into cash.
- Operating Cycle Drivers
- The expansion of the operating cycle is primarily driven by the lengthening of the inventory processing period. The increase of 40 days in inventory processing over the period is the dominant factor contributing to the total 47-day extension of the operating cycle, whereas the receivable collection period contributed only 7 days to the overall increase.
AI Ask an analyst for more
Average Payables Payment Period
| Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Payables turnover | 2.96 | 2.52 | 3.06 | 3.07 | 2.97 | 2.66 | 3.03 | 3.03 | 3.23 | 2.76 | 3.29 | 2.75 | 3.05 | 2.66 | 3.08 | 3.15 | 3.26 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||
| Average payables payment period1 | 123 | 145 | 119 | 119 | 123 | 137 | 120 | 121 | 113 | 132 | 111 | 133 | 120 | 137 | 118 | 116 | 112 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | — | 72 | 85 | 89 | 70 | 54 | 61 | 73 | 60 | 69 | 70 | 64 | 73 | 90 | 69 | 72 | 78 | ||||||
| Bristol-Myers Squibb Co. | 108 | 94 | 107 | 140 | 104 | 94 | 106 | 120 | 117 | 111 | 97 | 108 | 114 | 109 | 96 | 107 | 112 | ||||||
| Danaher Corp. | 64 | 67 | 63 | 65 | 66 | 66 | 60 | 63 | 62 | 65 | 65 | 63 | 64 | 67 | 65 | 73 | 72 | ||||||
| Eli Lilly & Co. | 148 | 178 | 154 | 161 | 140 | 140 | 135 | 142 | 127 | 134 | 130 | 138 | 119 | 106 | 86 | 87 | 70 | ||||||
| Gilead Sciences Inc. | — | 42 | 48 | 34 | 43 | 49 | 49 | 29 | 34 | 31 | 37 | 40 | 41 | 58 | 33 | 31 | 32 | ||||||
| Merck & Co. Inc. | — | 98 | 103 | 95 | 92 | 98 | 86 | 83 | 81 | 89 | 80 | 80 | 84 | 89 | 71 | 75 | 86 | ||||||
| Pfizer Inc. | — | 119 | 110 | 106 | 110 | 115 | 99 | 79 | 87 | 98 | 72 | 93 | 76 | 72 | 66 | 59 | 55 | ||||||
| Regeneron Pharmaceuticals Inc. | 163 | 163 | 158 | 129 | 129 | 146 | 94 | 110 | 137 | 122 | 106 | 116 | 136 | 138 | 98 | 91 | 68 | ||||||
| Thermo Fisher Scientific Inc. | — | 50 | 44 | 43 | 44 | 45 | 38 | 37 | 37 | 41 | 35 | 34 | 39 | 48 | 37 | 41 | 46 | ||||||
| Vertex Pharmaceuticals Inc. | — | 102 | 95 | 102 | 105 | 98 | 98 | 85 | 96 | 106 | 117 | 115 | 107 | 103 | 44 | 73 | 66 | ||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 2.96 = 123
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a cyclical pattern in the management of trade payables, characterized by recurring fluctuations in both turnover rates and the average duration of payment cycles.
- Payables Turnover Trends
- The payables turnover ratio exhibits a fluctuating trend, generally ranging between 2.52 and 3.29. A consistent downward trend is observed during the final quarter of each calendar year, with notable lows recorded in December 2022 (2.66), December 2023 (2.76), December 2024 (2.66), and December 2025 (2.52). Peaks in turnover are typically observed in the first and third quarters, indicating a more rapid settlement of obligations during these intervals.
- Average Payables Payment Period Analysis
- The average payables payment period demonstrates a strong inverse correlation with turnover, with durations fluctuating between a minimum of 111 days and a maximum of 145 days. A clear seasonal extension of payment terms is evident at year-end, with peaks occurring every December. The most significant extension was recorded in December 2025, reaching 145 days, while the shortest payment cycles were observed in October 2023 (111 days) and March 2024 (113 days).
- Working Capital Observations
- The data suggests a systemic tendency to extend payment terms toward the end of the fiscal year. This pattern indicates a strategic increase in the utilization of supplier credit to bolster short-term liquidity in the fourth quarter, followed by a contraction of the payment period in the subsequent quarters to normalize vendor relations and obligations.
AI Ask an analyst for more
Cash Conversion Cycle
| Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Average inventory processing period | 172 | 171 | 176 | 168 | 163 | 165 | 169 | 166 | 158 | 154 | 149 | 164 | 155 | 147 | 136 | 136 | 132 | ||||||
| Average receivable collection period | 67 | 67 | 70 | 72 | 65 | 61 | 67 | 67 | 64 | 64 | 62 | 68 | 65 | 62 | 60 | 62 | 60 | ||||||
| Average payables payment period | 123 | 145 | 119 | 119 | 123 | 137 | 120 | 121 | 113 | 132 | 111 | 133 | 120 | 137 | 118 | 116 | 112 | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Cash conversion cycle1 | 116 | 93 | 127 | 121 | 105 | 89 | 116 | 112 | 109 | 86 | 100 | 99 | 100 | 72 | 78 | 82 | 80 | ||||||
| Benchmarks | |||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | — | 216 | 195 | 200 | 216 | 222 | 234 | 270 | 349 | 441 | 277 | 285 | 290 | 273 | 282 | 267 | 245 | ||||||
| Danaher Corp. | 86 | 81 | 92 | 90 | 84 | 76 | 95 | 90 | 88 | 91 | 98 | 94 | 93 | 81 | 82 | 79 | 75 | ||||||
| Eli Lilly & Co. | 373 | 375 | 386 | 371 | 329 | 278 | 306 | 277 | 265 | 261 | 224 | 222 | 248 | 219 | 194 | 197 | 198 | ||||||
| Gilead Sciences Inc. | — | 124 | 122 | 135 | 116 | 107 | 111 | 143 | 130 | 132 | 132 | 123 | 118 | 104 | 104 | 105 | 100 | ||||||
| Merck & Co. Inc. | — | 116 | 126 | 135 | 120 | 107 | 129 | 138 | 138 | 118 | 123 | 126 | 116 | 93 | 106 | 106 | 113 | ||||||
| Pfizer Inc. | — | 192 | 224 | 202 | 188 | 173 | 207 | 173 | 155 | 120 | 124 | 113 | 91 | 63 | 94 | 96 | 96 | ||||||
| Regeneron Pharmaceuticals Inc. | 468 | 539 | 559 | 585 | 597 | 586 | 640 | 607 | 562 | 555 | 558 | 564 | 564 | 584 | 490 | 420 | 326 | ||||||
| Thermo Fisher Scientific Inc. | — | 98 | 112 | 110 | 104 | 97 | 112 | 107 | 105 | 101 | 111 | 112 | 106 | 97 | 111 | 116 | 118 | ||||||
| Vertex Pharmaceuticals Inc. | — | 333 | 335 | 304 | 274 | 242 | 229 | 211 | 190 | 166 | 154 | 137 | 131 | 112 | 150 | 120 | 122 | ||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 172 + 67 – 123 = 116
2 Click competitor name to see calculations.
The operating activity ratios indicate a general deterioration in working capital efficiency over the analyzed period, with the cash conversion cycle expanding from 80 days in April 2022 to 116 days by March 2026.
- Average Inventory Processing Period
- A persistent upward trend is observed in the inventory processing period, which rose from 132 days to 172 days. This steady increase represents the most significant factor contributing to the lengthening of the cash conversion cycle, suggesting a decline in inventory turnover efficiency.
- Average Receivable Collection Period
- The collection period remains relatively stable, fluctuating between a minimum of 60 days and a maximum of 72 days. While there is a slight upward drift beginning in 2023, the impact of receivable collection on the overall cash cycle is minimal compared to inventory movements.
- Average Payables Payment Period
- Payment periods exhibit high volatility, with values ranging from 111 to 145 days. Frequent fluctuations are evident, particularly with periodic spikes toward the end of calendar years, which serve to temporarily shorten the cash conversion cycle by delaying cash outflows to suppliers.
- Cash Conversion Cycle Trends
- The overall cash conversion cycle demonstrates a general trajectory of increase, peaking at 127 days in September 2025. The expansion of this cycle indicates that a greater amount of working capital is tied up in the operating process for longer durations, potentially limiting short-term liquidity.
AI Ask an analyst for more